Ipca Labs stock: Ipca Laboratories schedules November 5 results for Ipca Labs stock

Published on 10/23/2026 at 04:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Fiscal year 2026 revenue reached INR 96.5 billion, up 8.00 percent. Adjusted profit rose 27.00 percent as Ipca Labs stock enters the results window.

Upcoming results and earnings base

Ipca Laboratories scheduled its second-quarter results meeting for November 5, 2026.
Fiscal year 2026 revenue rose 8.00 percent to INR 96.5 billion.
Adjusted fiscal year 2026 profit increased 27.00 percent to INR 11.6 billion.
Ipca Laboratories had a market capitalization of INR 482.9 billion as of October 22, 2026.

Ipca Labs, INE571A01038, Illustration mit AI erstellt.

Ipca Laboratories (INE571A01038) increased fiscal year 2026 revenue 8.00 percent to INR 96.5 billion, while adjusted profit rose 27.00 percent to INR 11.6 billion. The company has scheduled its second-quarter and first-half results meeting for November 5, 2026, according to The Economic Times on October 22, 2026.

Results date sets the next test

The scheduled meeting covers unaudited standalone and consolidated results for the second quarter and first half ended September 30, 2026. That date gives investors a defined checkpoint for revenue growth, margins and cash generation after the company delivered a stronger fiscal year 2026.

The latest notice is the most immediate company-specific event in the reporting calendar. The results will also show whether the growth profile described in the previous annual cycle carried into the September period.

What does 27.00 percent profit growth show?

DSIJ reported that fiscal year 2026 adjusted profit reached INR 11.6 billion, up 27.00 percent, while revenue increased 8.00 percent. The difference points to earnings growth outpacing sales growth during the period.

The same report said fiscal year 2026 EBITDA rose 15.00 percent to INR 19.8 billion. Formulation revenue increased 10.00 percent to INR 38.2 billion, while export-formulation revenue also grew 10.00 percent to INR 20.8 billion.

Three dated operating milestones

On June 1, 2026, Motilal Oswal Financial Services kept its Buy view and a target of INR 1,730, as reported by DSIJ. On August 13, 2026, Ipca published its first-quarter fiscal year 2027 results notice, according to The Economic Times. On October 22, 2026, the company scheduled the November 5 results meeting.

Dates investors can mark

The next substantiated company date is November 5, 2026, for the second-quarter and first-half fiscal year 2027 results. The September 30, 2026 reporting period is the key reference for that release.

Valuation leaves a wide range

Ipca Laboratories had a market capitalization of INR 482.9 billion as of October 22, 2026. Its 52-week range was INR 1,251.60 to INR 2,038.00 on the same date, showing a broad trading envelope around the upcoming results event.